Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma

References

• Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:57–65.
   PubMed Web of Science ®Google Scholar
• Kumar S. Progress in the treatment of multiple myeloma. Lancet 2006;367:791–792.
   PubMed Web of Science ®Google Scholar
• Kumar S. Multiple myeloma - current issues and controversies. Cancer Treat Rev 2010;36(Suppl. 2):S3–S11.
   Google Scholar
• Anderson K, Jagannath S, Jakubowiak A, . Lenalidomide, bortezomib and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study. J Clin Oncol 2009;27(15 Suppl.):Abstract 8536.
   Google Scholar
• Kumar SK, Lacy MQ, Hayman SR, . Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol 2011;86: 640–645.
   PubMed Web of Science ®Google Scholar
• Laubach JP, Schlossman RL, Mitsiades CS, . Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol 2011;4:51–60.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, . Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002;99:14374–14379.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, . The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61: 3071–3076.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, . Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99: 4525–4530.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Jagannath S, . Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27: 5713–5719.
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, . International uniform response criteria for multiple myeloma. Leukemia 2006;20: 1467–1473.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, . Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117:4691–4695.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
   Google Scholar
• Blade J, Samson D, Reece D, . Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–1123.
   Google Scholar
• Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011; 17:1264–1277.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Mitsiades CS, Dimopoulos MA, . Management of relapsed and relapsed refractory myeloma. Hematol Oncol Clin North Am 2007;21:1175–1215, x.
   PubMed Web of Science ®Google Scholar
• Reece DE. Management of multiple myeloma: the changing landscape. Blood Rev 2007;21:301–314.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E. Lenalidomide: an update on evidence from clinical trials. Blood Rev 2010;24(Suppl. 1):S21–S26.
   Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y, . Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943–2950.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10:361–369.
   PubMedGoogle Scholar
• Richardson PG, Blood E, Mitsiades CS, . A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458–3464.
   PubMed Web of Science ®Google Scholar
• Richardson P, Mitsiades C, Laubach J, . Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid 2010;4:215–245.
   PubMedGoogle Scholar
• Richardson P, Jagannath S, Jakubowiak A, . Phase II clinical trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed/refractory MM: updated efficacy and safety data after > 2 years of follow-up. Blood 2010;116(Suppl. 1):Abstract 3049.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Richardson PG, Zimmerman T, . Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a phase I Multiple Myeloma Research Consortium study. Br J Haematol 2012;158:472–480.
   PubMed Web of Science ®Google Scholar
• Alsina M, Trudel S, Furman RR, . A phase 1 single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 2012 Jul 3. [Epub ahead of print]
   Web of Science ®Google Scholar